AC
SMMT icon

AXQ Capital’s Summit Therapeutics SMMT Stock Holding History

AXQ Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$896K Sell
47,268
-34,251
-42% -$554K 0.12% 265
2025
Q4 		$1.43M Buy
81,519
+64,051
+367% +$1.2M 0.32% 83
2025
Q3 		$361K Buy
+17,468
New +$424K 0.14% 268

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AXQ Capital's SMMT Position: Q1 2026 in Review

AXQ Capital reduced its Summit Therapeutics (SMMT) stake by 42% in Q1 2026, selling an estimated $554K and leaving 47,268 shares worth $896K. The position accounts for 0.12% of the portfolio, ranked #265.

AXQ Capital first reported a position in SMMT in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.43M in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • AXQ Capital held 47,268 shares of Summit Therapeutics worth $896K as of Q1 2026.
  • AXQ Capital sold 34,251 Summit Therapeutics shares in Q1 2026, an estimated $554K.
  • Summit Therapeutics made up 0.12% of AXQ Capital's portfolio in Q1 2026, its #265 holding.
  • AXQ Capital first reported a position in Summit Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • AXQ Capital's Summit Therapeutics position peaked at $1.43M in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.